Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9219 in Relapsed/Refractory Hematologic Malignancies
NCT00499239Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2007
- Primary completion
- Jul 2010
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of rabacfosadine in chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM), sponsored by Gilead Sciences. Started Jul 2007; status: terminated.
02
Drugs
rabacfosadine
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00499239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499239.